amount of KGF, thereby inducing a semi-synchronous wave of liver cell proliferation *in vivo*, and further comprising administering to a liver cell a retroviral vector complexed with cationic liposomes wherein the retroviral vector encodes HGF, which treats or prevents cirrhosis of the liver.

## IN THE SPECIFICATION

Please delete the paragraph beginning on page 7, line 18 and ending on page 8, line 9 and replace it with the following paragraph.

J.

The timing, dosage and mode of T3 administration should be determined by the prescribing physician or veterinarian, and may vary depending on the mode of administration, the species, age, and condition of the individual and in accordance with the needs of the individual and the time schedule of administration of other factors. T3 may be administered at any effective time before entrance of liver cells into S-phase is desired. T3 administration may also continue thereafter. Generally, however, T3 may be administered between about 0 and about 28 days before entrance of liver cells into S-phase is desired. Preferably, T3 is administered between about 6 days and about 14 days before entrance of liver cells into S-phase is desired. Most preferably, T3 is administered between about 24 hours and about 8 days before entrance of liver cells into S-phase is desired. More than one administration of T3 may be desirable in accordance with the needs of the individual as determined by the prescribing physician or veterinarian, and T3 may be administered any effective amount of times. Successive administrations generally can be performed at intervals ranging from about hourly to about weekly, but are preferably done at about daily intervals, or by continuous infusion. T3 administration may continue for any effective time after liver cells have begun to proliferate.

Please delete the paragraph beginning on page 10, line 11 and ending on page 10, line 15 and replace it with the following paragraph.

A triple combination of T3, KGF, and hepatocyte growth factor (HGF) was also tried. The cell proliferating characteristics and the transduction efficiency of the triple combination were not statistically significantly different from the T3/KGF combination, although in some experiments the total number of cells induced to proliferate and liver cells transduced may have been slightly higher.

The claims and paragraphs have been amended as shown in the attached Version With Markings to Show Changes. A clean version of all pending and allowed claims is found at the end of this paper.

Please note that the new attorney reference number is 54113-8004.US01.

The present amendments are made solely to advance prosecution of the present application and should not be construed as an admission of any kind. Broader claims will be pursued in a continuation application.